CO2020002989A2 - Ácidos nucleicos estabilizados que codifican el ácido ribonucleico mensajero (arnm) - Google Patents
Ácidos nucleicos estabilizados que codifican el ácido ribonucleico mensajero (arnm)Info
- Publication number
- CO2020002989A2 CO2020002989A2 CONC2020/0002989A CO2020002989A CO2020002989A2 CO 2020002989 A2 CO2020002989 A2 CO 2020002989A2 CO 2020002989 A CO2020002989 A CO 2020002989A CO 2020002989 A2 CO2020002989 A2 CO 2020002989A2
- Authority
- CO
- Colombia
- Prior art keywords
- mrna
- nucleic acids
- acids encoding
- ribonucleic acid
- messenger ribonucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545883P | 2017-08-15 | 2017-08-15 | |
| PCT/US2018/046772 WO2019036513A1 (en) | 2017-08-15 | 2018-08-14 | STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020002989A2 true CO2020002989A2 (es) | 2020-05-05 |
Family
ID=63638316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0002989A CO2020002989A2 (es) | 2017-08-15 | 2020-03-13 | Ácidos nucleicos estabilizados que codifican el ácido ribonucleico mensajero (arnm) |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11673911B2 (enExample) |
| EP (1) | EP3668980A1 (enExample) |
| JP (2) | JP2020532961A (enExample) |
| KR (2) | KR20250004924A (enExample) |
| CN (2) | CN111212908B (enExample) |
| AU (2) | AU2018318135B2 (enExample) |
| BR (1) | BR112020003026A2 (enExample) |
| CA (1) | CA3072960A1 (enExample) |
| CO (1) | CO2020002989A2 (enExample) |
| MX (1) | MX2020001821A (enExample) |
| WO (1) | WO2019036513A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3015369T3 (en) * | 2014-10-09 | 2025-05-05 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018129368A2 (en) | 2017-01-06 | 2018-07-12 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| JP2020532961A (ja) * | 2017-08-15 | 2020-11-19 | インテリア セラピューティクス，インコーポレイテッド | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 |
| CA3077391A1 (en) * | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | In vitro method of mrna delivery using lipid nanoparticles |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| US20240344019A1 (en) * | 2021-08-17 | 2024-10-17 | Sk Bioscience Co., Ltd. | Method for stably maintaining poly(a) tail |
| CA3238867A1 (en) | 2021-11-29 | 2023-06-01 | Shanghai Regenelead Therapies Co., Ltd. | Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| US20250388946A1 (en) * | 2022-05-31 | 2025-12-25 | Industry-Academic Cooperation Foundation Gyeongsang National University | Novel modified polyadenine sequence and use thereof |
| CN117701602A (zh) * | 2022-08-26 | 2024-03-15 | 深圳瑞吉生物科技有限公司 | 在宿主细胞中稳定存在的多段化PolyA多核苷酸及其应用 |
| JP2026507667A (ja) * | 2023-03-01 | 2026-03-04 | 仁景（▲蘇▼州）生物科技有限公司 | Ｒｎａをコードするための工学的に操作されたｄｎａ分子 |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| CN119799695A (zh) * | 2023-10-10 | 2025-04-11 | 深圳瑞吉生物科技有限公司 | 提高mRNA稳定性以及蛋白表达的多元polyA多核苷酸及其应用 |
| PL446809A1 (pl) * | 2023-11-22 | 2025-05-26 | Sieć Badawcza Łukasiewicz - PORT Polski Ośrodek Rozwoju Technologii | Cząsteczki RNA ze zmodyfikowanymi sekwencjami końca 3' i ich zastosowanie |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| GB202406051D0 (en) | 2024-04-30 | 2024-06-12 | Univ Oxford Innovation Ltd | Segmented poly(a) tails |
| TW202617987A (zh) | 2024-06-26 | 2026-05-01 | 美商英特利亞醫療公司 | 用於基因體編輯之經修飾之嚮導ｒｎａ |
| CN121628926A (zh) * | 2024-08-29 | 2026-03-10 | 仁景(苏州)生物科技有限公司 | 一种多价流感mRNA疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08131163A (ja) * | 1994-11-11 | 1996-05-28 | Sankyo Co Ltd | ドメイン変換ヘアピン型リボザイム |
| JP2002360299A (ja) * | 2001-04-20 | 2002-12-17 | Seiwa Technics:Kk | ｍＲＮＡの不安定性を利用したサイトカインの３’非翻訳領域を組み込んだトランスジェニックマウスのガン、炎症などの病変部位検出方法 |
| WO2012019630A1 (en) * | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2013120500A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2016005004A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| ES3015369T3 (en) | 2014-10-09 | 2025-05-05 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid |
| MA41349A (fr) * | 2015-01-14 | 2017-11-21 | Univ Temple | Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn |
| EP3085714B1 (en) * | 2015-04-21 | 2018-03-14 | Rohm And Haas Company | Co2 abating latex coating composition |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| KR101786396B1 (ko) | 2016-10-27 | 2017-11-24 | 서울대학교산학협력단 | 전령 rna의 3′말단 서열 분석 방법 |
| JP2020532961A (ja) * | 2017-08-15 | 2020-11-19 | インテリア セラピューティクス，インコーポレイテッド | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 |
-
2018
- 2018-08-14 JP JP2020508506A patent/JP2020532961A/ja active Pending
- 2018-08-14 MX MX2020001821A patent/MX2020001821A/es unknown
- 2018-08-14 EP EP18772961.1A patent/EP3668980A1/en active Pending
- 2018-08-14 CA CA3072960A patent/CA3072960A1/en active Pending
- 2018-08-14 KR KR1020247040420A patent/KR20250004924A/ko active Pending
- 2018-08-14 BR BR112020003026-0A patent/BR112020003026A2/pt not_active Application Discontinuation
- 2018-08-14 CN CN201880066328.XA patent/CN111212908B/zh active Active
- 2018-08-14 CN CN202510029728.5A patent/CN119899831A/zh active Pending
- 2018-08-14 KR KR1020207007211A patent/KR102740888B1/ko active Active
- 2018-08-14 WO PCT/US2018/046772 patent/WO2019036513A1/en not_active Ceased
- 2018-08-14 AU AU2018318135A patent/AU2018318135B2/en active Active
-
2020
- 2020-02-14 US US16/791,076 patent/US11673911B2/en active Active
- 2020-03-13 CO CONC2020/0002989A patent/CO2020002989A2/es unknown
-
2023
- 2023-05-01 US US18/310,298 patent/US12391722B2/en active Active
- 2023-08-25 JP JP2023137160A patent/JP2023179428A/ja active Pending
-
2024
- 2024-12-04 AU AU2024278094A patent/AU2024278094A1/en not_active Abandoned
-
2025
- 2025-07-22 US US19/276,658 patent/US20250346625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020001821A (es) | 2020-09-18 |
| CN119899831A (zh) | 2025-04-29 |
| US20200172564A1 (en) | 2020-06-04 |
| KR20250004924A (ko) | 2025-01-08 |
| AU2018318135A1 (en) | 2020-03-05 |
| WO2019036513A1 (en) | 2019-02-21 |
| AU2024278094A1 (en) | 2024-12-19 |
| CN111212908B (zh) | 2025-01-24 |
| KR102740888B1 (ko) | 2024-12-13 |
| US20230271997A1 (en) | 2023-08-31 |
| JP2023179428A (ja) | 2023-12-19 |
| BR112020003026A2 (pt) | 2020-08-25 |
| US11673911B2 (en) | 2023-06-13 |
| JP2020532961A (ja) | 2020-11-19 |
| US20250346625A1 (en) | 2025-11-13 |
| KR20200036025A (ko) | 2020-04-06 |
| CN111212908A (zh) | 2020-05-29 |
| EP3668980A1 (en) | 2020-06-24 |
| CA3072960A1 (en) | 2019-02-21 |
| AU2018318135B2 (en) | 2024-09-12 |
| US12391722B2 (en) | 2025-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001821A (es) | Ácidos nucleicos estabilizados que codifican el ácido ribonucleico mensajero (arnm). | |
| ES2657737T3 (es) | Vector dual para la inhibición del virus de la inmunodeficiencia humana | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| PY18107830A (es) | Variantes de alfa-amilasa y polinucleótidos que las codifican | |
| BR122021025194A8 (pt) | Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| MX2010002753A (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. | |
| PH12013502234A1 (en) | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same | |
| MX375911B (es) | Constructos de anticuerpo multiespecifico. | |
| CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
| MX385926B (es) | Proteínas de fusión de citoquinas. | |
| ATE527382T1 (de) | Dimere und trimere nukleinsäurefarbstoffe sowie systeme und verfahren in zusammenhang damit | |
| AR059433A1 (es) | Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas | |
| MX2024009272A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| ES2687294T3 (es) | Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos | |
| CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
| BR112012015740A2 (pt) | anticorpos de anti-flt3 e metodos de uso dos mesmos | |
| CL2021002262A1 (es) | Composiciones y métodos para tratar laminopatías | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| AR059650A1 (es) | Plantas que presentan aumento en el rendimiento y metodo para lograrlo | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| MX2017007105A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| AU2015286820A8 (en) | Stabilization of poly(A) sequence encoding DNA sequences |